Mga Batayang Estadistika
| CIK | 1461993 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Melinta Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| June 24, 2020 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) TETRAPHASE PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) TORONTO TRANSACTION CORP. a wholly owned subsidiary of MELINTA THERAPEUTICS, INC. (Names of Filing Persons (Offeror)) DEERF |
|
| June 24, 2020 |
Tetraphase Pharmaceuticals, Inc. 480 Arsenal Way, Suite 100 Watertown, MA 02472 EX-99.D.7 Exhibit (d)(7) Tetraphase Pharmaceuticals, Inc. 480 Arsenal Way, Suite 100 Watertown, MA 02472 June 23, 2020 Melinta Therapeutics, Inc. 44 Whippany Rd, Suite 280 Morristown, New Jersey 07960 Attention: Jennifer Sanfilippo Re: Mutual Termination Letter Agreement under Melinta Merger Agreement Dear Ms. Sanfilippo: Reference is made to (i) the Agreement and Plan of Merger dated June 4, 2020 |
|
| June 24, 2020 |
EX-99.A.5.B Exhibit (a)(5)(B) Melinta Therapeutics Announces Termination of Merger Agreement and Tender Offer for Shares of Tetraphase MORRISTOWN, N. J. June 24, 2020 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage antibiotics company, announced that on June 24, 2020, pursuant to the Agreement and Plan of Merger by and among Melinta, Toronto Transaction Corp. (“Purcha |
|
| June 12, 2020 |
SC TO-T 1 d935954dsctot.htm SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 TETRAPHASE PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) TORONTO TRANSACTION CORP. a wholly owned subsidiary of MELINTA THERAPEUTICS, INC. (Names of Filing Persons (Offeror |
|
| June 12, 2020 |
EX-99.A.1.D Exhibit (a)(1)(D) Offer To Purchase For Cash All Outstanding Shares of Common Stock of TETRAPHASE PHARMACEUTICALS, INC. a Delaware corporation at $1.79 NET PER SHARE IN CASH, PLUS ONE NON-TRANSFERABLE CONTRACTUAL CONTINGENT VALUE RIGHT (“CVR”) FOR EACH SHARE, WHICH REPRESENTS THE RIGHT TO RECEIVE ONE OR MORE PAYMENTS IN CASH, CURRENTLY ESTIMATED TO BE UP TO $1.48 PER CVR, CONTINGENT UP |
|
| June 12, 2020 |
EX-99.A.1.F Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely pursuant to the Offer to Purchase, dated June 12, 2020, and the related Letter of Transmittal, and any amendments or supplements to such Offer to Purchase or Letter of Transmittal. Purchaser (as defined below) |
|
| June 12, 2020 |
FORM OF UNSECURED MULTI-DRAW PROMISSORY NOTE Maximum Principal Amount: $[39,000,000] Dated: __, 2020 EX-99.B.1 Exhibit (b)(1) FORM OF UNSECURED MULTI-DRAW PROMISSORY NOTE Maximum Principal Amount: $[39,000,000] Dated: , 2020 Each of Toronto Transaction Corporation, a Delaware corporation (“Buyer”), and Melinta Therapeutics, Inc., a Delaware Corporation (“Melinta”) (Buyer and Melinta are hereinafter referred to collectively, jointly and severally, as the “Borrowers” and individually as a “Borrower |
|
| June 12, 2020 |
EX-99.D.2 Exhibit (d)(2) CONFIDENTIALITY AGREEMENT This Confidentiality Agreement (the “Agreement”) dated May 14, 2020 (the “Effective Date”), between Tetraphase Pharmaceuticals, Inc., a Delaware corporation, located at 480 Arsenal Way, Watertown, MA 02472 (the “Company”), and Melinta Therapeutics, Inc., located at 44 Whippany Road, Suite 280, Morristown, NJ 07960 (“Melinta”). 1. Background. The C |
|
| June 12, 2020 |
EX-99.A.1.A 2 d935954dex99a1a.htm EX-99.A.1.A Table of Contents Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of TETRAPHASE PHARMACEUTICALS, INC. At $1.79 Net Per Share In Cash, Plus One Non-Transferable Contractual Contingent Value Right (“CVR”) For Each Share, Which Represents The Right To Receive One Or More Payments In Cash, Currently Estimated To Be Up To $1.48 Pe |
|
| June 12, 2020 |
EX-99.D.5 Exhibit (d)(5) GUARANTEE This Guarantee (the “Guarantee”) is being entered into order to induce Tetraphase Pharmaceuticals, Inc., a Delaware corporation (“Tetraphase”), to enter into that certain Agreement and Plan of Merger, dated as of June 4, 2020 (as it may be amended or supplemented from time to time pursuant to the terms thereof, the “Merger Agreement”), by and among Tetraphase, Me |
|
| June 12, 2020 |
EX-99.A.1.C Exhibit (a)(1)(C) NOTICE OF GUARANTEED DELIVERY For Tender of Shares of Common Stock of TETRAPHASE PHARMACEUTICALS, INC. a Delaware corporation at $1.79 NET PER SHARE IN CASH, PLUS ONE NON-TRANSFERABLE CONTRACTUAL CONTINGENT VALUE RIGHT (“CVR”) FOR EACH SHARE, WHICH REPRESENTS THE RIGHT TO RECEIVE ONE OR MORE PAYMENTS IN CASH, CURRENTLY ESTIMATED TO BE UP TO $1.48 PER CVR, CONTINGENT U |
|
| June 12, 2020 |
EX-99.A.1.B Exhibit (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of TETRAPHASE PHARMACEUTICALS, INC. a Delaware corporation at $1.79 NET PER SHARE IN CASH, PLUS ONE NON-TRANSFERABLE CONTRACTUAL CONTINGENT VALUE RIGHT (“CVR”) FOR EACH SHARE, WHICH REPRESENTS THE RIGHT TO RECEIVE ONE OR MORE PAYMENTS IN CASH, CURRENTLY ESTIMATED TO BE UP TO $1.48 PER CVR, CONTINGENT UPON THE ACHI |
|
| June 12, 2020 |
EX-99.A.1.E Exhibit (a)(1)(E) Offer To Purchase For Cash All Outstanding Shares of Common Stock of TETRAPHASE PHARMACEUTICALS, INC. a Delaware corporation at $1.79 NET PER SHARE IN CASH, PLUS ONE NON-TRANSFERABLE CONTRACTUAL CONTINGENT VALUE RIGHT (“CVR”) FOR EACH SHARE, WHICH REPRESENTS THE RIGHT TO RECEIVE ONE OR MORE PAYMENTS IN CASH, CURRENTLY ESTIMATED TO BE UP TO $1.48 PER CVR, CONTINGENT UP |
|
| April 20, 2020 |
Amended and Restated By-Laws of Melinta Therapeutics, Inc. AMENDED AND RESTATED BY-LAWS OF MELINTA THERAPEUTICS, INC. These Amended and Restated By-laws of Melinta Therapeutics, Inc. were duly adopted in accordance with the provisions of Section 303 of the General Corporation Law of the State of Delaware (“DGCL”), pursuant to the authority granted to the Corporation under Section 303 of the DGCL to put into effect and carry out the Modified Amended Joint |
|
| April 20, 2020 |
MLNT / Melinta Therapeutics, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on April 20, 2020 Registration No. |
|
| April 20, 2020 |
MLNT / Melinta Therapeutics, Inc. S-8 POS - - S-8 POS S-8 POS 1 s-8pos204560.htm S-8 POS As filed with the Securities and Exchange Commission on April 20, 2020 Registration No. 333-181358 Registration No. 333-190891 Registration No. 333-204560 Registration No. 333-219881 Registration No. 333-221531 Registration No. 333-227179 Registration No. 333-227180 Registration No. 333-228445 Registration No. 333-231551 UNITED STATES SECURITIES AND EXCHANGE COMM |
|
| April 20, 2020 |
MLNT / Melinta Therapeutics, Inc. S-8 POS - - S-8 POS S-8 POS 1 s-8pos227180.htm S-8 POS As filed with the Securities and Exchange Commission on April 20, 2020 Registration No. 333-181358 Registration No. 333-190891 Registration No. 333-204560 Registration No. 333-219881 Registration No. 333-221531 Registration No. 333-227179 Registration No. 333-227180 Registration No. 333-228445 Registration No. 333-231551 UNITED STATES SECURITIES AND EXCHANGE COMM |
|
| April 20, 2020 |
MLNT / Melinta Therapeutics, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on April 20, 2020 Registration No. |
|
| April 20, 2020 |
8-K 1 a8-kxplanclosing.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 20, 2020 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdict |
|
| April 20, 2020 |
MLNT / Melinta Therapeutics, Inc. S-3DPOS - - S-3DPOS S-3DPOS 1 posamxs-3.htm S-3DPOS As filed with the Securities and Exchange Commission on April 20, 2020 Registration No. 333-190890 Registration No. 333-222484 Registration No. 333-222485 Registration No. 333-222487 Registration No. 333-222731 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-3 REGISTRATION STATEMENT NO. 333-190890 POST |
|
| April 20, 2020 |
EX-99.2 4 ex992pressreleasex04-16x20.htm EXHIBIT 99.2 Melinta Therapeutics Successfully Completes Financial Restructuring Company is Well-Positioned for Success as it Emerges from Chapter 11 In Partnership with Deerfield, Plans for Growth are Announced NEW YORK, NY, April 20, 2020—Commercial-stage antibiotics company Melinta Therapeutics (“Melinta”) and healthcare investment firm Deerfield Managem |
|
| April 20, 2020 |
MLNT / Melinta Therapeutics, Inc. S-8 POS - - S-8 POS S-8 POS 1 s-8pos.htm S-8 POS As filed with the Securities and Exchange Commission on April 20, 2020 Registration No. 333-181358 Registration No. 333-190891 Registration No. 333-204560 Registration No. 333-219881 Registration No. 333-221531 Registration No. 333-227179 Registration No. 333-227180 Registration No. 333-228445 Registration No. 333-231551 UNITED STATES SECURITIES AND EXCHANGE COMMISSION |
|
| April 20, 2020 |
MLNT / Melinta Therapeutics, Inc. S-3DPOS - - S-3DPOS S-3DPOS 1 posamxs-3x222484.htm S-3DPOS As filed with the Securities and Exchange Commission on April 20, 2020 Registration No. 333-190890 Registration No. 333-222484 Registration No. 333-222485 Registration No. 333-222487 Registration No. 333-222731 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-3 REGISTRATION STATEMENT NO. 333-1908 |
|
| April 20, 2020 |
MLNT / Melinta Therapeutics, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on April 20, 2020 Registration No. |
|
| April 20, 2020 |
MLNT / Melinta Therapeutics, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on April 20, 2020 Registration No. |
|
| April 20, 2020 |
MLNT / Melinta Therapeutics, Inc. S-3DPOS - - S-3DPOS As filed with the Securities and Exchange Commission on April 20, 2020 Registration No. |
|
| April 20, 2020 |
MLNT / Melinta Therapeutics, Inc. S-3DPOS - - S-3DPOS S-3DPOS 1 posamxs-3x222731.htm S-3DPOS As filed with the Securities and Exchange Commission on April 20, 2020 Registration No. 333-190890 Registration No. 333-222484 Registration No. 333-222485 Registration No. 333-222487 Registration No. 333-222731 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-3 REGISTRATION STATEMENT NO. 333-1908 |
|
| April 20, 2020 |
MLNT / Melinta Therapeutics, Inc. S-8 POS - - S-8 POS S-8 POS 1 s-8pos228445.htm S-8 POS As filed with the Securities and Exchange Commission on April 20, 2020 Registration No. 333-181358 Registration No. 333-190891 Registration No. 333-204560 Registration No. 333-219881 Registration No. 333-221531 Registration No. 333-227179 Registration No. 333-227180 Registration No. 333-228445 Registration No. 333-231551 UNITED STATES SECURITIES AND EXCHANGE COMM |
|
| April 20, 2020 |
MLNT / Melinta Therapeutics, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on April 20, 2020 Registration No. |
|
| April 20, 2020 |
MLNT / Melinta Therapeutics, Inc. S-3DPOS - - S-3DPOS S-3DPOS 1 posamxs-3x222485.htm S-3DPOS As filed with the Securities and Exchange Commission on April 20, 2020 Registration No. 333-190890 Registration No. 333-222484 Registration No. 333-222485 Registration No. 333-222487 Registration No. 333-222731 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-3 REGISTRATION STATEMENT NO. 333-1908 |
|
| April 20, 2020 |
Restated Certificate of Incorporation of Melinta Therapeutics, Inc. RESTATED CERTIFICATE OF INCORPORATION OF MELINTA THERAPEUTICS, INC. Melinta Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: 1.The name of the corporation is Melinta Therapeutics, Inc. and the name under which the corporation originally incorporated is Cempra, Inc. The date the or |
|
| April 14, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits, Bankruptcy or Receivership 8-K 1 a8-kxconfirmationorder.htm 8-K-CONFIRMATION ORDER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 11, 2020 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 |
|
| April 14, 2020 |
IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE MELINTA THERAPEUTICS, INC. |
|
| April 14, 2020 |
IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re Chapter 11 MELINTA THERAPEUTICS, INC. |
|
| February 18, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 7, 2020 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdiction of incorporation) (Co |
|
| February 18, 2020 |
EX-99.1 2 d881043dex991.htm EX-99.1 Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re Chapter 11 MELINTA THERAPEUTICS, INC., et al., Case No. 19-12748 (LSS) Debtors.1 Jointly Administered Related to Docket Nos. 15, 72, 260 NOTICE OF FINAL ORDER ESTABLISHING NOTICE AND HEARING PROCEDURES FOR TRADING IN, OR CLAIMS OF WORTHLESSNESS WITH RESPECT TO, EQUITY SECURITIE |
|
| January 8, 2020 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8-K 1 d861015d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 2, 2020 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdict |
|
| December 27, 2019 |
EX-99.1 Exhibit 99.1 Melinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders under its Senior Credit Facility ~ Company Initiates Voluntary Chapter 11 Process to Effectuate Restructuring Transaction While Continuing Normal-Course Operations ~ MORRISTOWN, N.J., December 27, 2019 – Melinta Therapeutics, Inc. (NASDAQ: MLNT) (the “Company” or “Melinta”), a commercial-st |
|
| December 27, 2019 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 27, 2019 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdiction of incorporatio |
|
| December 27, 2019 |
EX-10.1 Exhibit 10.1 RESTRUCTURING SUPPORT AGREEMENT AMONG MELINTA THERAPEUTICS, INC. AND THE SUPPORTING LENDERS IDENTIFIED HEREIN DATED AS OF DECEMBER 27, 2019 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS Section 1.1 Defined Terms 6 Section 1.2 Terms Defined Elsewhere in this Agreement 16 ARTICLE II DEFINITIVE DOCUMENTS Section 2.1 Incorporation of Exhibits and Schedules 18 Section 2.2 Definitive |
|
| November 12, 2019 |
Quarterly Report - 10-Q Q3 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-35405 MELINTA THERAPEUTICS, INC. |
|
| November 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 31, 2019 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdiction of incorporation) (Commis |
|
| October 24, 2019 |
EX-99.1 2 ex991pressrelease102519.htm EXHIBIT 99.1 Melinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) ~ Approval Based on Positive Phase III Trial Results of BAXDELA for Treatment of CABP in Adults~ ~ Company Delays Launch of CABP Indication Until Further Visibility Int |
|
| October 24, 2019 |
8-K 1 a8-kcapdpdufax102519.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 24, 2019 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jur |
|
| September 3, 2019 |
EX-10.1 2 d747520dex101.htm EX-10.1 Exhibit 10.1 SEPARATION AND RELEASE AGREEMENT This Separation and Release Agreement (this “Agreement”), delivered August 29, 2019, confirms the following understandings and agreements between Melinta Therapeutics, Inc., a Delaware corporation (the “Company”) and John H. Johnson (hereinafter referred to as “you” or “your”). In consideration of the promises set fo |
|
| September 3, 2019 |
8-K 1 d747520d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 28, 2019 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdict |
|
| September 3, 2019 |
EX-99.1 Exhibit 99.1 Melinta Therapeutics Announces Appointment of Jennifer Sanfilippo to Interim Chief Executive Officer and Director MORRISTOWN, N.J., September 3, 2019 – Melinta Therapeutics, Inc. (Nasdaq: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that Jennifer Sanfilippo has bee |
|
| August 13, 2019 |
Amendment No. 10 to Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 10) Melinta Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 58549G 100 (CUSIP Number) Anna Kim, Esq. Vatera Capital Management LLC 400 Royal Palm Way, Suite 212 Pa |
|
| August 9, 2019 |
Melinta Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update ~ Revenue of $16. |
|
| August 9, 2019 |
8-K 1 q22019earnings8-k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 9, 2019 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdic |
|
| August 9, 2019 |
Melinta Therapeutics Names David Gill as Chairman and Announces CEO Succession Plan ~ Company Initiates Search for New Chief Executive Officer ~ MORRISTOWN, N. |
|
| August 9, 2019 |
MLNT / Melinta Therapeutics, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-35405 MELINTA THERAPEUTICS, INC. |
|
| July 16, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events 8-K 1 melinta-xformx8xkxxxpress.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 16, 2019 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other j |
|
| July 16, 2019 |
Melinta Therapeutics Announces Preliminary Second Quarter 2019 Financial Results and Provides Corporate Update ~ Expects to Report Second Quarter 2019 Net Product Sales of Approximately $13. |
|
| July 2, 2019 |
SC 13D/A (Amendment No. 9) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 9) Melinta Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 58549G 100 (CUSIP Number) Anna Kim, Esq. Vatera Capital Management LLC 400 Royal Palm Way, Suite 212 Palm Beac |
|
| July 1, 2019 |
EX-10.1 Exhibit 10.1 EXECUTION VERSION FIRST AMENDMENT This FIRST AMENDMENT (this “Amendment”) is entered into as of June 28, 2019, by and among MELINTA THERAPEUTICS, INC., a Delaware corporation (the “Borrower”), the other Loan Parties party hereto and the Lenders party hereto. W I T N E S S E T H: WHEREAS, the Borrower, the other Loan Parties party thereto and the Lenders party thereto are parti |
|
| July 1, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 d736423d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 28, 2019 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdictio |
|
| June 10, 2019 |
Submission of Matters to a Vote of Security Holders 8-K 1 melinta-xformx8xkxxxannua.htm 8-K-ANNUAL MEETING RESULTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 10, 2019 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-44 |
|
| June 7, 2019 |
8-K 1 melinta-xformx8xkxxxlitxs.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 6, 2019 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other ju |
|
| May 16, 2019 |
Employment Inducement Stock Option Grant Agreement with Timothy Simon EX-99.1 Exhibit 99.1 MELINTA THERAPEUTICS, INC. NOTICE OF STOCK OPTION GRANT Melinta Therapeutics, Inc. (the “Company”), hereby grants to Optionholder an option to purchase the number of shares of Stock set forth below in accordance with that certain offer letter between Optionholder and the Company, delivered January 22, 2019, as may be amended, restated or otherwise modified from time to time (t |
|
| May 16, 2019 |
Employment Inducement Restricted Stock Unit Award Agreement with Timothy Simon EX-99.2 5 d749861dex992.htm EX-99.2 Exhibit 99.2 MELINTA THERAPEUTICS, INC. RESTRICTED STOCK UNIT AWARD GRANT NOTICE Melinta Therapeutics, Inc. (the “Company”), hereby grants to Participant an award of Restricted Stock Units as set forth below in accordance with that certain offer letter between Participant and the Company, delivered January 22, 2019, as may be amended, restated or otherwise modif |
|
| May 16, 2019 |
MLNT / Melinta Therapeutics, Inc. S-8 S-8 S-8 As filed with the Securities and Exchange Commission on May 16, 2019 Registration Statement No. |
|
| May 10, 2019 |
Separation and Release agreement with Erin Duffy, Ph.D. dated April 9, 2019. begin 644 mlnt033119ex101.pdf M)5!$1BTQ+C0-)>+CS],-"C8R(# @;V)J#3P\+TQI;F5A\ T*96YD%LP(# @ M-C$R(#7!E+U!A9V4^/@UE;F1O8FH- M-C4@,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E+TQE;F=T:" T-3X^<*! @P M $PL"[ -"F5N9'-T7!E+T]B:E-T;3X^ M^8:*IB9 Y4&V0$!0( ! )\N#P\-"F5N9'-T<@ M,"!O8FH-/#PO0FET2]$96-O9&5087)M$1E8V]D92](96EG:'0@,S,P,"],96YG=&@@ M,3 V,C8T+U-U8G1Y<&4O26UA9V4O5'EP92]83V)J96-T+U=I9'1H(#(U-3(^ M/G-T4U'(#RD |
|
| May 10, 2019 |
Melinta Amended and Restated 2018 Stock Incentive Plan dated February 19, 2019. MELINTA THERAPEUTICS, INC. AMENDED AND RESTATED 2018 STOCK INCENTIVE PLAN This AMENDED AND RESTATED 2018 STOCK INCENTIVE PLAN, originally established and adopted on June 12, 2018, by Melinta Therapeutics, Inc., a Delaware corporation, is hereby amended and restated effective February 19, 2019 (the “Restatement Date”). 1.Purpose. The purpose of the Plan is to assist the Company in attracting, retai |
|
| May 10, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-35405 MELINTA THERAPEUTICS, INC. |
|
| May 9, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2019 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdiction of incorporation) (Commission |
|
| May 9, 2019 |
Melinta Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update ~ Revenue of $14. |
|
| April 30, 2019 |
MLNT / Melinta Therapeutics, Inc. DEF 14A DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 14, 2019 |
10-K 1 mlnt-123118x10k.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-3540 |
|
| March 14, 2019 |
List of subsidiaries of Melinta Therapeutics, Inc. Exhibit 21.1 Subsidiaries of the Company Subsidiary Jurisdiction of Incorporation Cempra Pharmaceuticals, Inc. Delaware CEM-102 Pharmaceuticals, Inc. Delaware Melinta Subsidiary Corp. Delaware Rempex Pharmaceuticals, Inc. Delaware Targanta Therapeutics Corporation Delaware Rib-X Therapeutics Ltd United Kingdom Rempex London Limited United Kingdom |
|
| March 13, 2019 |
mlntq4andfullyear2018ear Fourth Quarter and Full-Year 2018 Earnings Conference Call Melinta Therapeutics, Inc. |
|
| March 13, 2019 |
Melinta Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results ~ Reports Revenue of $96. |
|
| March 13, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 13, 2019 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdiction of incorporation) (Commissi |
|
| February 26, 2019 |
SC 13D/A (Amendment No. 8) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 8) Melinta Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 58549G 100 (CUSIP Number) Anna Kim, Esq. Vatera Capital Management LLC 400 Royal Palm Way, Suite 212 Palm Beac |
|
| February 25, 2019 |
8-K 1 d711608d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 22, 2019 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdi |
|
| February 25, 2019 |
EX-10.2 Exhibit 10.2 Execution Version EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into this 22 day of February 2019, by and between Melinta Therapeutics, Inc., a Delaware corporation (the “Company”), and John Johnson (“Executive”). W I T N E S S E T H : WHEREAS, the Company currently employs Executive as Interim Chief Executive Officer of the Company purs |
|
| February 25, 2019 |
Certificate of Designations of Series A Convertible Preferred Stock of Melinta Therapeutics, Inc. EX-3.1 2 d711608dex31.htm EX-3.1 Exhibit 3.1 CERTIFICATE OF DESIGNATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK OF MELINTA THERAPEUTICS, INC. Melinta Therapeutics, Inc. (the “Company”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies, pursuant to Section 151 of the DGCL, that the following resolutions were duly adopted |
|
| February 25, 2019 |
EX-10.1 Exhibit 10.1 This Second Amended and Restated Senior Subordinated Convertible Loan Agreement (and the indebtedness and obligations evidenced hereby) are subordinate in the manner, and to the extent, set forth in that certain Subordination Agreement dated as of December 31, 2018 (as amended, restated, supplemented or otherwise modified from time to time, the “Subordination Agreement”) by an |
|
| February 21, 2019 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 19, 2019 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdiction of incorporatio |
|
| February 21, 2019 |
EX-3.1 2 d706276dex31.htm EXHIBIT 3.1 Exhibit 3.1 AMENDMENT TO CERTIFICATE OF INCORPORATION CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF MELINTA THERAPEUTICS, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware Melinta Therapeutics, Inc., a Delaware corporation (hereinafter called the “Corporation”), does hereby certify as follows: FIRST: The fir |
|
| February 21, 2019 |
Melinta Therapeutics Announces One-for-Five Reverse Stock Split Exhibit 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Melinta Therapeutics Announces One-for-Five Reverse Stock Split NEW HAVEN, Conn., February 21, 2019 – Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that its Board of Directors has approved a one-for-five |
|
| February 13, 2019 |
MLNT / Melinta Therapeutics, Inc. DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| February 13, 2019 |
CEMP / Cempra, Inc. / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Melinta Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 58549G100 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| February 4, 2019 |
EX-99.1 2 d666781dex991.htm EX-99.1 Exhibit 99.1 Melinta Therapeutics Provides Corporate Updates ~ Highlights Continued Positive Sales Momentum and Estimated Year-End Cash Position ~ ~ Confirms Previously Announced Cost Savings Guidance ~ ~ Continues Senior Leadership Team Evolution with New Management Appointments ~ NEW HAVEN, Conn., February 4, 2019 – Melinta Therapeutics, Inc. (NASDAQ: MLNT), a |
|
| February 4, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 4, 2019 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdiction of incorporation |
|
| February 4, 2019 |
MLNT / Melinta Therapeutics, Inc. FORM 8-K DEFA14A 1 d666781d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 4, 2019 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other juri |
|
| February 4, 2019 |
Press Release titled “Melinta Therapeutics Provides Corporate Updates” EX-99.1 Exhibit 99.1 Melinta Therapeutics Provides Corporate Updates ~ Highlights Continued Positive Sales Momentum and Estimated Year-End Cash Position ~ ~ Confirms Previously Announced Cost Savings Guidance ~ ~ Continues Senior Leadership Team Evolution with New Management Appointments ~ NEW HAVEN, Conn., February 4, 2019 – Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company fo |
|
| January 29, 2019 |
DEFR14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 16, 2019 |
CEMP / Cempra, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| January 15, 2019 |
EX-10.1 2 d689737dex101.htm EX-10.1 Exhibit 10.1 EXECUTION VERSION This Amended and Restated Senior Subordinated Convertible Loan Agreement (and the indebtedness and obligations evidenced hereby) are subordinate in the manner, and to the extent, set forth in that certain Subordination Agreement dated as of December 31, 2018 (as amended, restated, supplemented or otherwise modified from time to tim |
|
| January 15, 2019 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 14, 2019 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdiction of incorporation |
|
| January 15, 2019 |
EX-10.2 3 d689737dex102.htm EX-10.2 Exhibit 10.2 FIRST AMENDMENT TO FACILITY AGREEMENT This FIRST AMENDMENT TO FACILITY AGREEMENT (this “Amendment”) is entered into as of January 14, 2019, by and among MELINTA THERAPEUTICS, INC., a Delaware corporation (the “Borrower”), the other Loan Parties party hereto, the Lenders party hereto and Cortland Capital Market Services LLC, as agent for itself and t |
|
| January 15, 2019 |
EX-10.1 Exhibit 10.1 EXECUTION VERSION This Amended and Restated Senior Subordinated Convertible Loan Agreement (and the indebtedness and obligations evidenced hereby) are subordinate in the manner, and to the extent, set forth in that certain Subordination Agreement dated as of December 31, 2018 (as amended, restated, supplemented or otherwise modified from time to time, the “Subordination Agreem |
|
| January 15, 2019 |
EX-10.2 3 d689737dex102.htm EX-10.2 Exhibit 10.2 FIRST AMENDMENT TO FACILITY AGREEMENT This FIRST AMENDMENT TO FACILITY AGREEMENT (this “Amendment”) is entered into as of January 14, 2019, by and among MELINTA THERAPEUTICS, INC., a Delaware corporation (the “Borrower”), the other Loan Parties party hereto, the Lenders party hereto and Cortland Capital Market Services LLC, as agent for itself and t |
|
| January 15, 2019 |
MLNT / Melinta Therapeutics, Inc. FORM 8-K DEFA14A 1 d689737d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 14, 2019 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other juri |
|
| January 15, 2019 |
MLNT / Melinta Therapeutics, Inc. PRER14A PRER14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 3, 2019 |
EX-10.1 2 d681717dex101.htm EX-10.1 Exhibit 10.1 Execution Version This Senior Subordinated Convertible Loan Agreement (and the indebtedness and obligations evidenced hereby) are subordinate in the manner, and to the extent, set forth in that certain Subordination Agreement dated as of December 31, 2018 (as amended, restated, supplemented or otherwise modified from time to time, the “Subordination |
|
| January 3, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 31, 2018 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdiction of incorporation) (C |
|
| January 3, 2019 |
EX-10.1 Exhibit 10.1 Execution Version This Senior Subordinated Convertible Loan Agreement (and the indebtedness and obligations evidenced hereby) are subordinate in the manner, and to the extent, set forth in that certain Subordination Agreement dated as of December 31, 2018 (as amended, restated, supplemented or otherwise modified from time to time, the “Subordination Agreement”) by and among Me |
|
| January 3, 2019 |
MLNT / Melinta Therapeutics, Inc. 8-K DEFA14A 1 d681717d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 31, 2018 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdic |
|
| January 3, 2019 |
EX-12 Exhibit 12 JOINT FILING AGREEMENT In accordance with Rule 13d-l (k) (1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D dated January 3, 2019 (including amendments thereto) with respect to the Common Stock of Melinta Therapeutics, Inc. |
|
| January 3, 2019 |
SC 13D/A (Amendment No. 7) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 7) Melinta Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 58549G 100 (CUSIP Number) Anna Kim, Esq. Vatera Capital Management LLC 400 Royal Palm Way, Suite 212 Palm Beac |
|
| December 20, 2018 |
SC 13D/A 1 d637403dsc13da.htm SC 13D/A (AMENDMENT NO. 6) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6) Melinta Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 58549G 100 (CUSIP Number) Anna Kim, Esq. Vatera Holdings LLC 499 Park Ave, 23rd |
|
| December 19, 2018 |
MLNT / Melinta Therapeutics, Inc. DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| December 19, 2018 |
MLNT / Melinta Therapeutics, Inc. DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| December 19, 2018 |
8-K 1 d674882d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 18, 2018 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35405 45-4440364 (State or other jurisdi |
|
| December 19, 2018 |
EX-10.1 2 d674882dex101.htm EX-10.1 Exhibit 10.1 December 18, 2018 Melinta Therapeutics, Inc. 300 George Street Suite 301 New Haven, Connecticut 06511 Re: Financing Commitment Ladies and Gentlemen: Melinta Therapeutics, Inc. (the “Borrower”) has requested that Vatera Healthcare Partners LLC (“VHP”) and Vatera Investment Partners LLC (“VIP” and, collectively with VHP, the “Initial Lenders”) provide |
|
| December 19, 2018 |
EX-10.1 Exhibit 10.1 December 18, 2018 Melinta Therapeutics, Inc. 300 George Street Suite 301 New Haven, Connecticut 06511 Re: Financing Commitment Ladies and Gentlemen: Melinta Therapeutics, Inc. (the “Borrower”) has requested that Vatera Healthcare Partners LLC (“VHP”) and Vatera Investment Partners LLC (“VIP” and, collectively with VHP, the “Initial Lenders”) provide the Borrower with an up to |
|
| December 19, 2018 |
MLNT / Melinta Therapeutics, Inc. FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 18, 2018 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35405 45-4440364 (State or other jurisdiction of incorporatio |
|
| December 10, 2018 |
MLNT / Melinta Therapeutics, Inc. DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| November 29, 2018 |
MLNT / Melinta Therapeutics, Inc. DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| November 21, 2018 |
SC 13D/A 1 d638269dsc13da.htm SC 13D/A (AMENDMENT NO. 5) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5) Melinta Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 58549G 100 (CUSIP Number) Anna Kim, Esq. Vatera Holdings LLC 499 Park Ave, 23rd |
|
| November 19, 2018 |
EX-10.1 Exhibit 10.1 PURCHASE AGREEMENT dated as of November 19, 2018 by and between Melinta Therapeutics, Inc. and Vatera Healthcare Partners LLC TABLE OF CONTENTS Page ARTICLE I PURCHASE; CLOSING 1.1 Purchase 1 1.2 Closing 1 1.3 Closing Conditions 1 ARTICLE II REPRESENTATIONS AND WARRANTIES 2.1 Representations and Warranties of the Company 2 2.2 Representations and Warranties of the Purchaser 5 |
|
| November 19, 2018 |
8-K 1 d652813d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 19, 2018 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdi |
|
| November 19, 2018 |
MLNT / Melinta Therapeutics, Inc. PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| November 16, 2018 |
MLNT / Melinta Therapeutics, Inc. POST-EFFECTIVE AMENDMENT NO.1 TO FORM S-8 S-8 POS 1 d636069ds8pos.htm POST-EFFECTIVE AMENDMENT NO.1 TO FORM S-8 As filed with the Securities and Exchange Commission on November 16, 2018 Registration Statement No. 333-227179 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MELINTA THERAPEUTICS, INC. (Exact Name of Regis |
|
| November 16, 2018 |
MLNT / Melinta Therapeutics, Inc. FORM S-8 S-8 1 d621614ds8.htm FORM S-8 As filed with the Securities and Exchange Commission on November 16, 2018 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MELINTA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 45-4440364 (State or other jurisdict |
|
| November 8, 2018 |
SC 13D/A 1 d651380dsc13da.htm SC 13D/A (AMENDMENT NO. 4) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4) Melinta Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 58549G 100 (CUSIP Number) Anna Kim, Esq. Vatera Holdings LLC 499 Park Ave, 23rd |
|
| November 7, 2018 |
EX-99.2 4 d635446dex992.htm EX-99.2 THE ANTIBIOTICS COMPANY . Q3 2018 Earnings Conference Call Melinta Therapeutics, Inc. Exhibit 99.2 This presentation contains forward-looking statements that involve a number of risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding our strategy, future operations, future f |
|
| November 7, 2018 |
EX-10.1 Exhibit 10.1 November 6, 2018 Melinta Therapeutics, Inc. 300 George Street Suite 301 New Haven, CT 06511 Re: Financing Commitment Ladies and Gentlemen: 1. Commitment. This letter confirms the commitment of Vatera Healthcare Partners LLC (the “Investor”) to purchase (or cause an assignee permitted by the terms of Section 3 hereof to purchase), at any time and from time to time prior to Dece |
|
| November 7, 2018 |
8-K 1 d635446d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 6, 2018 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdic |
|
| November 7, 2018 |
EX-99.1 3 d635446dex991.htm EX-99.1 Exhibit 99.1 Melinta Therapeutics Reports Third Quarter 2018 Financial Results - New Product Launches Continue to Make Progress Setting the Stage for Growth in 2019 - - Entered Commercial Agreement with Menarini Group to market Vabomere®, Orbactiv® and Minocin® for Injection in 68 Countries Outside the U.S. – - Positive opinion for Vabomere from the CHMP of the |
|
| November 7, 2018 |
[***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. |
|
| November 7, 2018 |
MLNT / Melinta Therapeutics, Inc. 10-Q (Quarterly Report) 10-Q 1 mlnt-093018x10q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: |
|
| November 7, 2018 |
Change in Control and Severance Agreement with Peter J. Milligan dated September 17, 2018 August 27, 2018 Peter Milligan 13 Crest Drive Randolph, NJ 07869 RE: Severance Agreement Dear Peter: Effective as of your commencement of employment with Melinta Therapeutics, Inc. |
|
| November 7, 2018 |
[***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. |
|
| November 7, 2018 |
Employment Agreement with Peter J. Milligan dated September 17, 2018 August 31, 2018 Peter Milligan 13 Crest Drive Randolph, NJ 07869 Via Email Delivery Dear Peter, We are pleased to offer you employment at Melinta Therapeutics, Inc. |
|
| November 7, 2018 |
Employment Inducement Stock Option Agreement with Peter J. Milligan MELINTA THERAPEUTICS, INC. NOTICE OF STOCK OPTION GRANT Melinta Therapeutics, Inc. (the “Company”), hereby grants to Optionholder an option to purchase the number of shares of Stock set forth below in accordance with that certain offer letter between Optionholder and the Company, dated August 31, 2018, as may be amended, restated or otherwise modified from time to time (the “Offer Letter”). This o |
|
| November 5, 2018 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 31, 2018 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdiction of incorporation |
|
| November 2, 2018 |
CEMP / Cempra, Inc. / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Melinta Therapeutics, Inc. (Name of Issuer) common stock, $0.001 par value (Title of Class of Securities) 58549G100 (CUSIP Number) October 24, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| October 24, 2018 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 18, 2018 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdiction of incorporation |
|
| October 24, 2018 |
Side Letter Agreement with Daniel Mark Wechsler, dated October 23, 2018 EX-10.2 Exhibit 10.2 October 23, 2018 Mr. Daniel Mark Wechsler Address on file with the Company Dear Dan, Reference is hereby made to the employment agreement by and between you and Melinta Therapeutics, Inc. (together with its subsidiaries, “Melinta”), dated October 30, 2017 (the “Employment Agreement”), and the Restricted Stock Unit Award Grant Notice and the Restricted Stock Unit Award Agreemen |
|
| October 24, 2018 |
Melinta Therapeutics Announces Appointment of John H. Johnson as Interim Chief Executive Officer EX-99.1 Exhibit 99.1 Melinta Therapeutics Announces Appointment of John H. Johnson as Interim Chief Executive Officer New Haven, Conn., October 22, 2018 – Melinta Therapeutics, Inc., (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, announced today that its board of directors has appointed John H. Johnson |
|
| October 24, 2018 |
Employment Agreement, dated October 22, 2018, between Melinta Therapeutics, Inc. and John H. Johnson EX-10.1 2 d635978dex101.htm EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into this this 22nd day of October 2018, by and between Melinta Therapeutics, Inc., a Delaware corporation (the “Company”), and John Johnson (“Executive”). W I T N E S S E T H : WHEREAS, the Company desires to employ Executive and to enter into this Agreement embod |
|
| October 5, 2018 |
EX-10.1 Exhibit 10.1 SEPARATION AND RELEASE AGREEMENT This Separation and Release Agreement (this “Agreement”), delivered September 17, 2018, confirms the following understandings and agreements between Melinta Therapeutics, Inc., a Delaware corporation (the “Company”) and Paul Estrem (hereinafter referred to as “you” or “your”). In consideration of the promises set forth herein, you and the Compa |
|
| October 5, 2018 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 3, 2018 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdiction of incorporation) |
|
| October 2, 2018 |
Entry into a Material Definitive Agreement Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 28, 2018 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdiction of incorporati |
|
| September 27, 2018 |
Entry into a Material Definitive Agreement 8-K 1 d631444d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 26, 2018 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisd |
|
| September 19, 2018 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 17, 2018 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdiction of incorporati |
|
| September 19, 2018 |
EX-99.1 Exhibit 99.1 PRESS RELEASE Melinta Therapeutics Names Peter Milligan as Chief Financial Officer SEPTEMBER 18, 2018 NEW HAVEN, Conn., Sept. 18, 2018 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that the company has appointed Peter M |
|
| September 4, 2018 |
MLNT / Melinta Therapeutics, Inc. FORM S-8 S-8 1 d611984ds8.htm FORM S-8 As filed with the Securities and Exchange Commission on September 4, 2018 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MELINTA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 45-4440364 (State or other jurisdict |
|
| September 4, 2018 |
MLNT / Melinta Therapeutics, Inc. FORM S-8 S-8 1 d604537ds8.htm FORM S-8 As filed with the Securities and Exchange Commission on September 4, 2018 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MELINTA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 45-4440364 (State or other jurisdict |
|
| August 9, 2018 |
Amendment No. 1 to D. Wechsler Employment Agreement, dated May 17, 2018 + Exhibit 10.2 AmendmenT No. 1 TO eMPLOYMENT AGREEMENT This Amendment No. 1 (this “Amendment”) to that certain Employment Agreement (as defined below) is entered into as of May 17, 2018, by and between Melinta Therapeutics, Inc., a Delaware corporation (the “Company”) and Daniel Mark Wechsler (the “Executive”). WHEREAS, the Company and Executive are parties to that certain Employment Agreement, date |
|
| August 9, 2018 |
MLNT / Melinta Therapeutics, Inc. MELINTA Q2 10-Q (Quarterly Report) 10-Q 1 mlnt-10q20180630.htm MELINTA Q2 10-Q 33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission Fi |
|
| August 7, 2018 |
EX-99.1 Exhibit 99.1 Melinta Therapeutics Reports Second Quarter 2018 Financial Results Solid Performance from New Product Launches Vabomere™ Granted NTAP Status by CMS Strengthened Financial Position Supports Continued Growth Completed Expansion and Cross-Training of Experienced Anti-infective Sales Force NEW HAVEN, Conn., August 7, 2018 – Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-s |
|
| August 7, 2018 |
EX-99.2 3 d567569dex992.htm EX-99.2 Melinta Therapeutics The Antibiotics Company . Q2 2018 Earnings Conference Call August 7, 2018 Exhibit 99.2 Cautionary Note Regarding Forward-looking Statements This presentation contains forward-looking statements that involve a number of risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including |
|
| August 7, 2018 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 7, 2018 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdiction of incorporation) |
|
| June 14, 2018 |
8-K 1 d585389d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 12, 2018 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdictio |
|
| June 14, 2018 |
EX-10.2 Exhibit 10.2 MELINTA THERAPEUTICS, INC. 2018 STOCK INCENTIVE PLAN NOTICE OF STOCK OPTION GRANT Melinta Therapeutics, Inc. (the “Company”), pursuant to its 2018 Stock Incentive Plan, as amended (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of Stock set forth below, subject to the stockholders of the Company approving the Plan. This option grant (the |
|
| June 14, 2018 |
EX-10.1 Exhibit 10.1 MELINTA THERAPEUTICS, INC. 2018 STOCK INCENTIVE PLAN NOTICE OF STOCK OPTION GRANT Melinta Therapeutics, Inc. (the “Company”), pursuant to its 2018 Stock Incentive Plan, as amended (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of Stock set forth below, subject to the stockholders of the Company approving the Plan. This option grant (the |
|
| June 8, 2018 |
EX-10.14 Exhibit 10.14 [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO THE RULES APPLICABLE TO SUCH CONFIDENTIAL TREATMENT REQUEST. AMENDED AND RESTATED LICENSE AGREEMENT This Amended and Restated License Agreement (this “Agreement”) is made this firs |
|
| June 8, 2018 |
EX-10.17 3 d587657dex1017.htm EX-10.17 Exhibit 10.17 [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO THE RULES APPLICABLE TO SUCH CONFIDENTIAL TREATMENT REQUEST. LICENSE AND SUPPLY AGREEMENT THIS LICENSE AND SUPPLY AGREEMENT (this “Agreement”) is made |
|
| June 8, 2018 |
Financial Statements and Exhibits 8-K/A 1 d587657d8ka.htm FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 14, 2018 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jur |
|
| May 31, 2018 |
SC 13D/A 1 d558616dsc13da.htm SC 13D/A (AMENDMENT NO. 3) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3) Melinta Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 58549G 100 (CUSIP Number) Anna Kim, Esq. Vatera Holdings LLC 499 Park Ave, 23rd |
|
| May 29, 2018 |
Underwriting Agreement, dated May 23, 2018 EX-1.1 Exhibit 1.1 EXECUTION VERSION Melinta Therapeutics, Inc. 22,000,000 Shares of Common Stock Underwriting Agreement May 23, 2018 J.P. Morgan Securities LLC Jefferies LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10017 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 Ladies and Ge |
|
| May 29, 2018 |
EX-99.3 Exhibit 99.3 Melinta Therapeutics Announces Closing of Underwritten Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock NEW HAVEN, Conn., May 29, 2018 – Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announc |
|
| May 29, 2018 |
Melinta Therapeutics Announces Proposed Offering of Common Stock EX-99.1 Exhibit 99.1 Melinta Therapeutics Announces Proposed Offering of Common Stock NEW HAVEN, Conn., May 21, 2018 – Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that it has commenced an underwritten public offering of shares of its common stock to raise a |
|
| May 29, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 d593903d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 23, 2018 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdiction |
|
| May 29, 2018 |
Melinta Therapeutics Announces Pricing of Public Offering of Common Stock EX-99.2 5 d593903dex992.htm EX-99.2 Exhibit 99.2 Melinta Therapeutics Announces Pricing of Public Offering of Common Stock NEW HAVEN, Conn., May 23, 2018 – Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced the pricing of an underwritten public offering of 22,000, |
|
| May 25, 2018 |
Joint Book-Running Managers J.P. Morgan Jefferies Lead Manager 424B5 1 d536574d424b5.htm 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No.: 333-222731 Prospectus Supplement (To Prospectus dated February 6, 2018) 22,000,000 shares Common stock We are offering 22,000,000 shares of our common stock as described in this prospectus supplement and the accompanying prospectus. Our common stock is listed on the NASDAQ Global Market under the s |
|
| May 21, 2018 |
Melinta Therapeutics Announces Proposed Offering of Common Stock FWP Issuer Free Writing Prospectus dated May 21, 2018 Filed Pursuant to Rule 433 Relating to Preliminary Prospectus Supplement dated May 21, 2018 Registration No. |
|
| May 21, 2018 |
Joint Book-Running Managers J.P. Morgan Jefferies Lead Manager 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No.: 333-222731 The information in this prospectus supplement is not complete and may be changed. This prospectus supplement and the accompanying prospectus is not an offer to sell these securities in any state or other jurisdiction where the offer or sale is not permitted. Subject to completion, dated May 21, 2018 Prospectus Su |
|
| May 11, 2018 |
Melinta Therapeutics, Inc. 2018 Stock Incentive Plan DEF 14A 1 mlnt-def14a20180612.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| May 10, 2018 |
MLNT / Melinta Therapeutics, Inc. 2018 Q1 10-Q (Quarterly Report) 33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-35405 MELINTA THERAPEUTICS, INC. |
|
| May 9, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 8, 2018 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdiction of incorporation) (Commiss |
|
| May 9, 2018 |
EX-99.2 3 d584957dex992.htm EX-99.2 Melinta Therapeutics The Antibiotics Company . Q1 2018 Earnings Conference Call May 8, 2018 Exhibit 99.2 Cautionary Note Regarding Forward-looking Statements This presentation contains forward-looking statements that involve a number of risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including sta |
|
| May 9, 2018 |
EX-99.1 Exhibit 99.1 Melinta Therapeutics Reports First Quarter 2018 Financial Results Strong Product Sales Performance Across Entire Portfolio Continuing to Optimize Operations to Achieve Cost Synergies Important Achievements for Development and Discovery Efforts Including CARB-X Funding Award NEW HAVEN, Conn., May 8, 2018 – Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company di |
|
| April 30, 2018 |
MLNT / Melinta Therapeutics, Inc. 2017 10-K/A (Annual Report) 10-K/A 1 mlnt-10ka20171231.htm 2017 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K/A (Amendment No. 1) ☒ (ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from t |
|
| March 27, 2018 |
EX-99.1 2 d558459dex991.htm EX-99.1 Melinta Therapeutics The Antibiotics Company Needham Healthcare Conference March 27, 2018 . Exhibit 99.1 Cautionary Note Regarding Forward-looking Statements This presentation contains forward-looking statements that involve a number of risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including sta |
|
| March 27, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 d558459d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 27, 2018 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdiction of |
|
| March 16, 2018 |
List of subsidiaries of Melinta Therapeutics, Inc. Exhibit 21.1 Subsidiaries of the Company Subsidiary Jurisdiction of Incorporation Cempra Pharmaceuticals, Inc. Delaware CEM-102 Pharmaceuticals, Inc. Delaware Melinta Subsidiary Corp. Delaware Rempex Pharmaceuticals, Inc. Delaware Targanta Therapeutics Corporation Delaware Rib-X Therapeutics Ltd United Kingdom Rempex London Limited United Kingdom Rempex Australia Pty Ltd. Australia |
|
| March 16, 2018 |
MLNT / Melinta Therapeutics, Inc. MLNT 2017 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-35405 MELINTA THERAPEUTICS, INC. |
|
| March 14, 2018 |
EX-10.3 Exhibit 10.3 Execution Version August 29, 2017 Paul Estrem 13 N Lake Ave. Third Lake, IL 60030 RE: Amended and Restated Severance Agreement Dear Paul: You are a key member of the senior management team of Melinta Therapeutics, Inc. (the “Company”). As a result, the Company is providing you with the following benefits in consideration of your continued employment with the Company. I. Defini |
|
| March 14, 2018 |
EX-10.5 Exhibit 10.5 November 18, 2013 Ms. Sue Cammarata 630 North State St. Unit 1106 Chicago, IL 60654 Dear Sue, We are very pleased to offer you employment at Melinta Therapeutics, Inc. (“Melinta”). Your start date will be effective as of November 18, 2013. We are very enthusiastic about your joining the Melinta team, and are confident of a mutually beneficial relationship. Position and Compens |
|
| March 14, 2018 |
EX-10.14 16 d549418dex1014.htm EX-10.14 [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO THE RULES APPLICABLE TO SUCH CONFIDENTIAL TREATMENT REQUEST. Exhibit 10.14 AMENDED AND RESTATED LICENSE AGREEMENT This Amended and Restated License Agreement (this |
|
| March 14, 2018 |
EX-10.4 Exhibit 10.4 EMPLOYEE NONCOMPETITION, NONDISCLOSURE AND DEVELOPMENTS AGREEMENT This Employee Noncompetition, Nondisclosure and Developments Agreement (the “Agreement”) is entered into as of December 9, 2013 (the “Effective Date”) by and between Paul Estrem the undersigned employee and Melinta Therapeutics, Inc., its parents, affiliates and subsidiaries (the “Company”). NOW THEREFORE, in co |
|
| March 14, 2018 |
Amendment No. 1 to the Cempra, Inc. 2011 Equity Incentive Plan, as amended May 21, 2015. EX-10.1 3 d549418dex101.htm EX-10.1 Exhibit 10.1 AMENDMENT NO. 1 TO THE CEMPRA, INC. 2011 EQUITY INCENTIVE PLAN This Amendment No. 1 (this “Amendment”) to the Cempra, Inc. 2011 Equity Incentive Plan, as amended from time to time (the “Plan”), is made effective as of March 9, 2018. WHEREAS, on November 3, 2017, Cempra, Inc., a Delaware corporation (the “Company”), completed its business combination |
|
| March 14, 2018 |
EX-10.10 Exhibit 10.10 EMPLOYEE NONCOMPETITION, NONDISCLOSURE AND DEVELOPMENTS AGREEMENT This Employee Noncompetition, Nondisclosure and Developments Agreement (the “Agreement”) is entered into by and between the undersigned employee and Rib-X Pharmaceuticals, Inc., its parents, affiliates and subsidiaries (the “Company”). WHEREAS, the Company is in negotiations with investors to obtain critical f |
|
| March 14, 2018 |
EX-10.18 19 d549418dex1018.htm EX-10.18 Exhibit 10.18 AMENDMENT This Amendment (the “Amendment”) to the License Agreement dated as of December 23, 2005 (the “Agreement”), is effective as of January 6, 2009 (“Amendment Effective Date”), between Eli Lilly and Company, a corporation organized and existing under the laws of the State of Indiana (“Lilly”), and Targanta Therapeutics Corporation, a corpo |
|
| March 14, 2018 |
EX-10.2 4 d549418dex102.htm EX-10.2 Exhibit 10.2 March 16, 2015 Mr. Paul Estrem 325 Clarewood Circle Grayslake, IL 60030 Dear Paul, OFFER OF EMPLOYMENT As we have discussed, we are pleased to offer you continued employment at Melinta Therapeutics, Inc. (“Melinta”) as its Chief Financial Officer (“CFO”), with the understanding that, at the discretion of Melinta, your title will change to that of Ch |
|
| March 14, 2018 |
EX-10.6 Exhibit 10.6 Execution Version August 29, 2017 Sue Cammarata 630 N State Street # 1106 Chicago, IL 60654 RE: Amended and Restated Severance Agreement Dear Sue: You are a key member of the senior management team of Melinta Therapeutics, Inc. (the “Company”). As a result, the Company is providing you with the following benefits in consideration of your continued employment with the Company. |
|
| March 14, 2018 |
EX-4.1 Exhibit 4.1 Explanatory Note: Due to adjustments resulting from the transactions contemplated by the Agreement and Plan of Merger and Reorganization, dated as of August 8, 2017, by and between Melinta Therapeutics, Inc. (f/k/a Cempra, Inc.), Castle Acquisition Corp. and Melinta Subsidiary Corp. (f/k/a Melinta Therapeutics, Inc.), which were consummated on November 3, 2017, the below warrant |
|
| March 14, 2018 |
EX-10.9 11 d549418dex109.htm EX-10.9 Exhibit 10.9 Execution Version August 29, 2017 Erin Duffy 349 River Road Deep River, CT 06417 RE: Amended and Restated Severance Agreement Dear Erin: You are a key member of the senior management team of Melinta Therapeutics, Inc. (the “Company”). As a result, the Company is providing you with the following benefits in consideration of your continued employment |
|
| March 14, 2018 |
EX-10.8 10 d549418dex108.htm EX-10.8 Exhibit 10.8 Rib-X Pharmaceuticals, Inc. 25 Science Park New Haven, CT 06511 Phone 203-624-5606 FAX 203-624-5627 December 2, 2001 Dr. Erin Duffy 349 River Road Deep River, CT 06417 Dear Dr. Duffy, Thank you for your interest in career opportunities at Rib-X Pharmaceuticals, Inc. (the “Company”). Since we believe your talent would be an asset to our young and dy |
|
| March 14, 2018 |
EX-10.13 Exhibit 10.13 Execution Version August 29, 2017 John Temporato 9900 Cape Scott Court Raleigh, NC 27614 RE: Amended and Restated Severance Agreement Dear John: You are a key member of the senior management team of Melinta Therapeutics, Inc. (the “Company”). As a result, the Company is providing you with the following benefits in consideration of your continued employment with the Company. |
|
| March 14, 2018 |
EX-10.16 18 d549418dex1016.htm EX-10.16 Exhibit 10.16 SEPARATION AND RELEASE AGREEMENT This Separation and Release Agreement (this “Agreement”), delivered December 21, 2017, confirms the following understandings and agreements between Melinta Therapeutics, Inc., a Delaware corporation (the “Company”) and John Temperato (hereinafter referred to as “you” or “your”). In consideration of the promises |
|
| March 14, 2018 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 13, 2018 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdiction of incorporation) (Comm |
|
| March 14, 2018 |
EX-10.7 9 d549418dex107.htm EX-10.7 Exhibit 10.7 EMPLOYEE NONCOMPETITION, NONDISCLOSURE AND DEVELOPMENTS AGREEMENT This Employee Noncompetition, Nondisclosure and Developments Agreement (the “Agreement”) is entered into by and between Sue Cammarata and Melinta Therapeutics, Inc., its parents, affiliates and subsidiaries (the “Company”). NOW THEREFORE, in consideration of my employment by the Compa |
|
| March 14, 2018 |
EX-10.15 17 d549418dex1015.htm EX-10.15 Exhibit 10.15 Master Manufacturing Services Agreement EXECUTION COPY Master Manufacturing Services Agreement 1st July, 2016 Master Manufacturing Services Agreement Table of Contents ARTICLE 1 4 STRUCTURE OF AGREEMENT AND INTERPRETATION 4 1.1 Master Agreement 4 1.2 Product Agreements 4 1.3 Definitions 4 1.4 Currency 12 1.5 Sections and Headings 12 1.6 Singula |
|
| March 14, 2018 |
EX-10.12 14 d549418dex1012.htm EX-10.12 Exhibit 10.12 EMPLOYEE NONCOMPETITION, NONDISCLOSURE AND DEVELOPMENTS AGREEMENT This Employee Noncompetition, Nondisclosure and Developments Agreement (the “Agreement”) is entered into as of February 16, 2016 (the “Effective Date”) by and between John Temperato the undersigned employee and Melinta Therapeutics, Inc., its parents, affiliates and subsidiaries |
|
| March 14, 2018 |
EX-10.11 13 d549418dex1011.htm EX-10.11 Exhibit 10.11 February 5, 2016 John Temperato President and Chief Operating Officer Melinta Therapeutics, Inc. RE: Severance Agreement Dear John: Effective as of February 16, 2016, you will be a key member of the senior management team of Melinta Therapeutics, Inc. (the “Company”). As a result, the Company is providing you with the following benefits in cons |
|
| March 13, 2018 |
EX-99.2 Melinta Therapeutics The Antibiotics Company Q4 2017 Earnings Conference Call March 13, 2018 . Exhibit 99.2 Cautionary Note Regarding Forward-looking Statements This presentation contains forward-looking statements that involve a number of risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding our str |
|
| March 13, 2018 |
EX-99.1 2 d437470dex991.htm EX-99.1 Exhibit 99.1 Melinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results Baxdela™(delafloxacin) Launched February 6, 2018, in U.S. for Adults with ABSSSI Acquired Infectious Disease Business from The Medicines Company on January 5, 2018 First Earnings Report as a Public Company NEW HAVEN, Conn., March 13, 2018 – Melinta Therapeutics, Inc. (N |
|
| March 13, 2018 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 13, 2018 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdiction of incorporation) |
|
| February 2, 2018 |
CORRESP 1 filename1.htm February 2, 2018 VIA EDGAR Ms. Christine Westbrook United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Melinta Therapeutics, Inc. Registration Statement on Form S-3 (Registration No. 333-222731) Dear Ms. Westbrook: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Melinta |
|
| January 26, 2018 |
S-3 1 d531693ds3.htm S-3 Table of Contents As filed with the Securities and Exchange Commission on January 26, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Melinta Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 45-4440364 (State or other jurisdi |
|
| January 26, 2018 |
Form of Debt Security (included in Exhibit 4.1) EX-4.1 2 d531693dex41.htm EX-4.1 Exhibit 4.1 MELINTA THERAPETUICS, INC. and [ ] , as Trustee INDENTURE DATED AS OF CROSS REFERENCE TABLE TIA Section Indenture Section 310(a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) N.A. (a)(5) N.A. (b) 7.08; 7.10 311(a) 7.11 (b) 7.11 312(a) 2.07 (b) 12.04 (c) 12.04 313(a) 7.06 (b)(1) 7.06 (b)(2) 7.06 (c) 7.06 (d) 7.06 314(a)(1) 4.02 (a)(2) 12.03 (a)(4) 4.04 (b) N.A. |
|
| January 23, 2018 |
CORRESP 1 filename1.htm January 23, 2018 VIA EDGAR Mr. Jeffrey Gabor United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Melinta Therapeutics, Inc. Registration Statement on Form S-3 (Registration No. 333-222485) Dear Mr. Gabor: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Melinta Therapeut |
|
| January 23, 2018 |
CORRESP January 23, 2018 VIA EDGAR Mr. Jeffrey Gabor United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Melinta Therapeutics, Inc. Registration Statement on Form S-3 (Registration No. 333-222487) Dear Mr. Gabor: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Melinta Therapeutics, Inc. (the ? |
|
| January 23, 2018 |
CORRESP 1 filename1.htm January 23, 2018 VIA EDGAR Mr. Jeffrey Gabor United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Melinta Therapeutics, Inc. Registration Statement on Form S-3 (Registration No. 333-222484) Dear Mr. Gabor: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Melinta Therapeut |
|
| January 22, 2018 |
CEMP / Cempra, Inc. AMENDMENT NO. 1 TO FORM S-3 Amendment No. 1 to Form S-3 Table of Contents As filed with the Securities and Exchange Commission on January 22, 2018 Registration No. 333-222485 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Melinta Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 45-444 |
|
| January 22, 2018 |
CEMP / Cempra, Inc. AMENDMENT NO. 1 TO FORM S-3 S-3/A 1 d492423ds3a.htm AMENDMENT NO. 1 TO FORM S-3 Table of Contents As filed with the Securities and Exchange Commission on January 22, 2018 Registration No. 333-222487 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Melinta Therapeutics, Inc. (Exact name of registrant as specified in its |
|
| January 22, 2018 |
CEMP / Cempra, Inc. AMENDMENT NO. 1 TO FORM S-3 Amendment No. 1 to Form S-3 Table of Contents As filed with the Securities and Exchange Commission on January 22, 2018 Registration No. 333-222484 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Melinta Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 45-444 |
|
| January 22, 2018 |
CORRESP 1 filename1.htm January 22, 2018 VIA EDGAR Mr. Jeffrey Gabor United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Melinta Therapeutics, Inc. Registration Statement on Form S-3 Filed January 9, 2018 File No. 333-222487 Dear Mr. Gabor: We are responding to the oral comment on January 17, 2018 of the Staff (the “Staff”) |
|
| January 22, 2018 |
CORRESP January 22, 2018 VIA EDGAR Mr. Jeffrey Gabor United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Melinta Therapeutics, Inc. Registration Statement on Form S-3 Filed January 9, 2018 File No. 333-222485 Dear Mr. Gabor: We are responding to the oral comment on January 17, 2018 of the Staff (the ?Staff?) of the Securiti |
|
| January 22, 2018 |
CORRESP 1 filename1.htm January 22, 2018 VIA EDGAR Mr. Jeffrey Gabor United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Melinta Therapeutics, Inc. Registration Statement on Form S-3 Filed January 9, 2018 File No. 333-222484 Dear Mr. Gabor We are responding to the oral comment on January 17, 2018 of the Staff (the “Staff”) |
|
| January 11, 2018 |
CEMP / Cempra, Inc. / Medicines Co /de - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 10, 2018 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 9, 2018 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdiction of incorporation) (Commi |
|
| January 10, 2018 |
EX-10.2 Exhibit 10.2 Execution Version FACILITY AGREEMENT dated as of January 5, 2018 by and among Melinta Therapeutics, Inc., as the Borrower, the other Loan Parties party hereto from time to time, the Lenders and Cortland Capital Market Services LLC, as Agent for itself and the Lenders Table of Contents ARTICLE 1 DEFINITIONS 1 Section 1.1 General Definitions 1 Section 1.2 Interpretation 26 Secti |
|
| January 9, 2018 |
Letter, dated November 28, 2017, by and between Vatera and the Company EX-10.2 Exhibit 10.2 CONFIDENTIAL November 28, 2017 Melinta Therapeutics, Inc. 300 George Street Suite 301 New Haven, CT 06511 Re: Equity Financing Commitment Ladies and Gentlemen: Reference is made to that certain Purchase and Sale Agreement, dated as of the date hereof (as amended, supplemented or modified from time to time, the ?Purchase Agreement?), by and among Melinta Therapeutics, Inc., a D |
|
| January 9, 2018 |
S-3 1 d492423ds3.htm FORM S-3 Table of Contents As filed with the Securities and Exchange Commission on January 9, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Melinta Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 45-4440364 (State or other jur |
|
| January 9, 2018 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on January 9, 2018 Registration No. |
|
| January 9, 2018 |
S-3 1 d517642ds3.htm FORM S-3 Table of Contents As filed with the Securities and Exchange Commission on January 9, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Melinta Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 45-4440364 (State or other jur |
|
| January 9, 2018 |
EX-10.1 Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of January 5, 2018, is by and among Melinta Therapeutics, Inc., a Delaware corporation (the “Company”), and the investors listed on Schedule I hereto (individually, a “Buyer” and, collectively, the “Buyers”). The Company and the Buyers shall be collectively referred |
|
| January 9, 2018 |
EX-10.2 8 d522242dex102.htm EX-10.2 Exhibit 10.2 Execution Version FACILITY AGREEMENT dated as of January 5, 2018 by and among Melinta Therapeutics, Inc., as the Borrower, the other Loan Parties party hereto from time to time, the Lenders and Cortland Capital Market Services LLC, as Agent for itself and the Lenders Table of Contents ARTICLE 1 DEFINITIONS 1 Section 1.1 General Definitions 1 Section |
|
| January 9, 2018 |
EX-10.3 9 d522242dex103.htm EX-10.3 Exhibit 10.3 Execution Version ROYALTY AGREEMENT This ROYALTY AGREEMENT (this “Agreement”), dated January 5, 2018, is made by and between Deerfield Private Design Fund IV, L.P. (“DPDF IV”), Deerfield Private Design Fund III, L.P. (“DPDF III”), Deerfield Special Situations Fund, L.P. (“DSS” and, collectively with DPDF IV and DPDF III, the “Initial Royalty Holders |
|
| January 9, 2018 |
CEMP / Cempra, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| January 9, 2018 |
Exhibit 99.1 Melinta Therapeutics Completes Acquisition of The Medicines Company?s Infectious Disease Portfolio ? Expands portfolio to four marketed antibiotics, with peak sales potential over $1 billion ? ? Creates premier commercial stage global antibiotic franchise with the addition of Vabomere? (meropenem and vaborbactam), Orbactiv? (oritavancin), and Minocin? (minocycline) for Injection ? ? M |
|
| January 9, 2018 |
EX-4.5 Exhibit 4.5 Execution Version THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAW. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRAT |
|
| January 9, 2018 |
EX-4.2 3 d522242dex42.htm EX-4.2 Exhibit 4.2 Execution Version REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of January 5, 2018, by and among Melinta Therapeutics, Inc., a Delaware corporation (the “Company”), and Deerfield Private Design Fund IV, L.P., Deerfield Private Design Fund III, L.P. and Deerfield Special Situations Fund, L.P. (each individually, |
|
| January 9, 2018 |
EX-4.4 Exhibit 4.4 Execution Version THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAW. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRAT |
|
| January 9, 2018 |
8-K 1 d522242d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 5, 2018 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdict |
|
| January 9, 2018 |
EX-4.3 Exhibit 4.3 Execution Version THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAW. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRAT |
|
| January 9, 2018 |
EX-4.1 2 d522242dex41.htm EX-4.1 Exhibit 4.1 EXECUTION VERSION REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT, dated as of January 5, 2018 (this “Agreement”), is made between Melinta Therapeutics, Inc., a Delaware corporation (the “Company”) and The Medicines Company, a Delaware Corporation (the “Shareholder”). A. On November 28, 2017, the Company and the Shareholder entered into |
|
| January 8, 2018 |
MLNT / Melinta Therapeutics, Inc. / Vatera Holdings Llc - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2) Melinta Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 58549G 100 (CUSIP Number) Anna Kim, Esq. Vatera Holdings LLC 499 Park Ave, 23rd Floor New York, NY 10022 (212) 590-2950 With a c |
|
| January 8, 2018 |
EX-99.6 Exhibit 6 JOINT FILING AGREEMENT In accordance with Rule 13d-l (k) (1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D dated January 8, 2018 (including amendments thereto) with respect to the Common Stock of Melinta Therapeutics, Inc. This Joint Filing Agreement shall be filed |
|
| January 3, 2018 |
8-K 1 d518416d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 31, 2017 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdi |
|
| December 27, 2017 |
Submission of Matters to a Vote of Security Holders Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 27, 2017 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdiction of incorporatio |
|
| December 15, 2017 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 6, 2017 |
Financial Statements and Exhibits 8-K/A 1 d465338d8ka.htm FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 5, 2017 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other j |
|
| December 5, 2017 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| December 5, 2017 |
MELINTA’S MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS EX-99.3 Exhibit 99.3 MELINTA’S MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis should be read in conjunction with Melinta’s 2016 audited consolidated financial statements included elsewhere in this document. This discussion and analysis contains forward-looking statements based upon current beliefs, plans and assumptions, |
|
| December 5, 2017 |
Financial Statements and Exhibits 8-K/A 1 d444924d8ka.htm FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 5, 2017 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other j |
|
| December 5, 2017 |
EX-99.1 Exhibit 99.1 Melinta Therapeutics, Inc. Financial Statements as of December 31, 2016 and 2015, and for the Years Ended December 31, 2016, 2015 and 2014, and Report of Independent Registered Public Accounting Firm MELINTA THERAPEUTICS, INC. TABLE OF CONTENTS Page(s) Report of Independent Registered Public Accounting Firm 2 Consolidated Financial Statements Consolidated Balance Sheets 4 Cons |
|
| December 5, 2017 |
UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS Exhibit 99.4 UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS Melinta Therapeutics, Inc. Unaudited Pro Forma Combined Financial Information The unaudited pro forma combined financial statements give effect to the merger with Cempra, Inc. that closed on November 3, 2017 (the ?Merger?). The term ?the combined company? as used in this proxy statement refers to the new Melinta Therapeutics, Inc. foll |
|
| December 5, 2017 |
EX-99.2 Exhibit 99.2 MELINTA THERAPEUTICS, INC. INDEX TO UNAUDITED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2017 Page(s) Condensed Consolidated Balance Sheets 2 Condensed Consolidated Statements of Operations 3 Condensed Consolidated Statements of Cash Flows 4 Notes to Unaudited Condensed Consolidated Financial Statements 5 to 20 1 MELINTA THERAPEUTICS, INC. UNAUDITED |
|
| December 4, 2017 |
Financial Statements and Exhibits, Other Events 8-K 1 d466551d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2017 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdi |
|
| December 4, 2017 |
Melinta Therapeutics (Update Call) November 29, 2017 EX-99.1 Exhibit 99.1 Important Information and Where to Find It Melinta will file a proxy statement with the SEC in connection with the proposed transactions. The proxy statement will be sent to the stockholders of Melinta. Melinta stockholders are advised to read the proxy statement when it becomes available, because it will contain important information about Melinta, and the proposed transactio |
|
| December 4, 2017 |
DEFA14A 1 d466551d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2017 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jur |
|
| December 4, 2017 |
Transcript of Melinta Therapeutics, Inc. investor conference call, held on November 29, 2017. EX-99.1 2 d466551dex991.htm EX-99.1 Exhibit 99.1 Important Information and Where to Find It Melinta will file a proxy statement with the SEC in connection with the proposed transactions. The proxy statement will be sent to the stockholders of Melinta. Melinta stockholders are advised to read the proxy statement when it becomes available, because it will contain important information about Melinta, |
|
| December 1, 2017 |
EX-4.2 4 d500891dex42.htm EX-4.2 Exhibit 4.2 VOTING AGREEMENT This Voting Agreement (this “Agreement”) is made and entered into as of November 28, 2017, between The Medicines Company, a Delaware corporation (“MedCo”), and the Persons whose names appear on the signature pages hereto (each such Person, a “Stockholder” and, collectively, the “Stockholders”). Capitalized terms used but not otherwise d |
|
| December 1, 2017 |
Letter, dated November 28, 2017, by and between JWC Rib-X LLC and Melinta Therapeutics, Inc. EX-4.4 6 d500891dex44.htm EX-4.4 Exhibit 4.4 CONFIDENTIAL November 28, 2017 Melinta Therapeutics, Inc. 300 George Street Suite 301 New Haven, CT 06511 Re: Equity Financing Commitment Ladies and Gentlemen: Reference is made to that certain Purchase and Sale Agreement, dated as of the date hereof (as amended, supplemented or modified from time to time, the “Purchase Agreement”), by and among Melinta |
|
| December 1, 2017 |
EX-4.3 5 d500891dex43.htm EX-4.3 Exhibit 4.3 CONFIDENTIAL November 28, 2017 Melinta Therapeutics, Inc. 300 George Street Suite 301 New Haven, CT 06511 Re: Equity Financing Commitment Ladies and Gentlemen: Reference is made to that certain Purchase and Sale Agreement, dated as of the date hereof (as amended, supplemented or modified from time to time, the “Purchase Agreement”), by and among Melinta |
|
| December 1, 2017 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2017 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35405 45-4440364 (State or other jurisdiction of incorporatio |
|
| December 1, 2017 |
EX-4.2 Exhibit 4.2 VOTING AGREEMENT This Voting Agreement (this “Agreement”) is made and entered into as of November 28, 2017, between The Medicines Company, a Delaware corporation (“MedCo”), and the Persons whose names appear on the signature pages hereto (each such Person, a “Stockholder” and, collectively, the “Stockholders”). Capitalized terms used but not otherwise defined herein shall have t |
|
| December 1, 2017 |
EX-4.1 Exhibit 4.1 VOTING AGREEMENT This Voting Agreement (this “Agreement”) is made and entered into as of November 28, 2017, between The Medicines Company, a Delaware corporation (“MedCo”), and the Persons whose names appear on the signature pages hereto (each such Person, a “Stockholder” and, collectively, the “Stockholders”). Capitalized terms used but not otherwise defined herein shall have t |
|
| December 1, 2017 |
Exhibit 10.1 CONFIDENTIAL November 28, 2017 Melinta Therapeutics, Inc. 300 George Street Suite 301 New Haven, Connecticut 06511 Attention: Paul Estrem, Chief Financial Officer Re: Project Grouper Commitment Letter Senior Secured Credit Facility, Equity Investment and Warrants Ladies and Gentlemen: You have advised the investment funds managed by Deerfield Management Company, L.P. (?Deerfield?) tha |
|
| December 1, 2017 |
EX-4.3 5 d500891dex43.htm EX-4.3 Exhibit 4.3 CONFIDENTIAL November 28, 2017 Melinta Therapeutics, Inc. 300 George Street Suite 301 New Haven, CT 06511 Re: Equity Financing Commitment Ladies and Gentlemen: Reference is made to that certain Purchase and Sale Agreement, dated as of the date hereof (as amended, supplemented or modified from time to time, the “Purchase Agreement”), by and among Melinta |
|
| December 1, 2017 |
EX-2.1 2 d500891dex21.htm EX-2.1 Exhibit 2.1 EXECUTION VERSION PURCHASE AND SALE AGREEMENT dated as of November 28, 2017 by and between THE MEDICINES COMPANY and MELINTA THERAPEUTICS, INC. TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS 1 1.1. Definitions 1 1.2. Construction 24 1.3. Performance of Obligations by Affiliates 24 ARTICLE II. PURCHASE AND SALE 25 2.1. Agreement to Purchase and Sell 25 2. |
|
| December 1, 2017 |
Letter, dated November 28, 2017, by and between JWC Rib-X LLC and Melinta Therapeutics, Inc. EX-4.4 Exhibit 4.4 CONFIDENTIAL November 28, 2017 Melinta Therapeutics, Inc. 300 George Street Suite 301 New Haven, CT 06511 Re: Equity Financing Commitment Ladies and Gentlemen: Reference is made to that certain Purchase and Sale Agreement, dated as of the date hereof (as amended, supplemented or modified from time to time, the “Purchase Agreement”), by and among Melinta Therapeutics, Inc., a Del |
